Mitchell Kaye

1.3k total citations
15 papers, 440 citations indexed

About

Mitchell Kaye is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Rheumatology. According to data from OpenAlex, Mitchell Kaye has authored 15 papers receiving a total of 440 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 5 papers in Physiology and 2 papers in Rheumatology. Recurrent topics in Mitchell Kaye's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (10 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (4 papers) and Sarcoidosis and Beryllium Toxicity Research (3 papers). Mitchell Kaye is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (10 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (4 papers) and Sarcoidosis and Beryllium Toxicity Research (3 papers). Mitchell Kaye collaborates with scholars based in United States, Germany and France. Mitchell Kaye's co-authors include Lewis J. Smith, Bruno Crestani, Manuel Quaresma, Michael Kreuter, Wibke Stansen, Susanne Stowasser, Takashi Ogura, Ian Glaspole, John T. Huggins and Ulrich Costabel and has published in prestigious journals such as CHEST Journal, Thorax and Molecular Plant-Microbe Interactions.

In The Last Decade

Mitchell Kaye

14 papers receiving 431 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mitchell Kaye United States	9	336	186	54	50	48	15	440
Susumu Isogai Japan	12	172 0.5×	203 1.1×	35 0.6×	4 0.1×	16 0.3×	21	360
Carah B. Santos United States	8	36 0.1×	192 1.0×	28 0.5×	11 0.2×	29 0.6×	11	369
Lei Cheng Sweden	11	84 0.3×	45 0.2×	33 0.6×	10 0.2×	132 2.8×	29	315
Miguel Pedroza-Seres United States	10	60 0.2×	64 0.3×	94 1.7×	11 0.2×	33 0.7×	33	414
Louise Organ Australia	10	218 0.6×	37 0.2×	15 0.3×	3 0.1×	53 1.1×	16	301
Ifat Sarouk Israel	11	215 0.6×	42 0.2×	20 0.4×	7 0.1×	122 2.5×	31	384
Damien Adam Canada	11	228 0.7×	55 0.3×	7 0.1×	6 0.1×	89 1.9×	29	382
Tomokazu Matsuoka Japan	11	41 0.1×	196 1.1×	11 0.2×	11 0.2×	34 0.7×	31	402
Jackie Zurcher United States	7	195 0.6×	550 3.0×	64 1.2×	2 0.0×	44 0.9×	9	699
Regina Smolarski Germany	9	40 0.1×	135 0.7×	40 0.7×	3 0.1×	35 0.7×	11	348

Countries citing papers authored by Mitchell Kaye

Since Specialization

Citations

This map shows the geographic impact of Mitchell Kaye's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mitchell Kaye with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mitchell Kaye more than expected).

Fields of papers citing papers by Mitchell Kaye

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mitchell Kaye. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mitchell Kaye. The network helps show where Mitchell Kaye may publish in the future.

Co-authorship network of co-authors of Mitchell Kaye

This figure shows the co-authorship network connecting the top 25 collaborators of Mitchell Kaye. A scholar is included among the top collaborators of Mitchell Kaye based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mitchell Kaye. Mitchell Kaye is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Mira‐Avendano, Isabel & Mitchell Kaye. (2024). Key learnings from the INBUILD trial in patients with progressive pulmonary fibrosis. Therapeutic Advances in Respiratory Disease. 18. 2693845671–2693845671. 1 indexed citations

Mammen, Manoj J., Tara F. Carr, Gerard J. Criner, et al.. (2021). All-Cause Mortality by Subgroup in Patients with Chronic Obstructive Pulmonary Disease: Post Hoc Analysis of the IMPACT Trial. A2241–A2241. 1 indexed citations

Bansal, Sandeep, Martin Anderson, Antonio Anzueto, et al.. (2021). Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD. npj Primary Care Respiratory Medicine. 31(1). 29–29. 9 indexed citations

Lancaster, Lisa, Jonathan Goldin, Matthias Trampisch, et al.. (2020). Effects of Nintedanib on Quantitative Lung Fibrosis Score in Idiopathic Pulmonary Fibrosis. The Open Respiratory Medicine Journal. 14(1). 22–31. 30 indexed citations

Crestani, Bruno, John T. Huggins, Mitchell Kaye, et al.. (2018). Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON. The Lancet Respiratory Medicine. 7(1). 60–68. 161 indexed citations

Crestani, Bruno, Manuel Quaresma, Mitchell Kaye, et al.. (2018). Long-term nintedanib treatment in idiopathic pulmonary fibrosis (IPF): final data from INPULSIS-ON. PA5230–PA5230. 1 indexed citations

Crestani, Bruno, Manuel Quaresma, Mitchell Kaye, et al.. (2017). Long-term nintedanib treatment in idiopathic pulmonary fibrosis (IPF): new data from INPULSIS-ON. OA3402–OA3402. 9 indexed citations

Crestani, Bruno, Manuel Quaresma, Mitchell Kaye, et al.. (2016). Long-term treatment with nintedanib in patients with IPF: An update from INPULSIS®-ON. OA4960–OA4960. 14 indexed citations

Crestani, Bruno, Takashi Ogura, Carl Coeck, et al.. (2015). Interim analysis of nintedanib in an open-label extension of the INPULSIS® trials (INPULSIS®-ON). OA4495–OA4495. 7 indexed citations

10.

Kaye, Mitchell, et al.. (2015). Efficacy and Safety of Nintedanib in US and Non-US Patients With Idiopathic Pulmonary Fibrosis (IPF) in the INPULSIS Trials. CHEST Journal. 148(4). 394A–394A. 2 indexed citations

11.

Pfeifer, Marija, Vincent Cottin, H. Taniguchi, et al.. (2015). Effect of baseline emphysema on reduction in FVC decline with nintedanib in the INPULSIS™ trials. Pneumologie. 69(S 01). 11 indexed citations

12.

Crestani, Bruno, Takashi Ogura, Carl Coeck, et al.. (2015). P7 Interim analysis of nintedanib in an open-label extension of the INPULSIS® trials (INPULSIS®-ON). Thorax. 70(Suppl 3). A77.3–A78. 2 indexed citations

13.

Matthysse, Ann G., Mazz Marry, Leonard Krall, et al.. (2005). The Effect of Cellulose Overproduction on Binding and Biofilm Formation on Roots by Agrobacterium tumefaciens. Molecular Plant-Microbe Interactions. 18(9). 1002–1010. 69 indexed citations

14.

Joyce, Lyle D., et al.. (2002). Feasibility and Value of Video-Assisted Thoracoscopic Surgery Wedge Excision of Small Pulmonary Nodules in Patients with Malignancy. CHEST Journal. 122(4). 1467–1470. 60 indexed citations

15.

Kaye, Mitchell & Lewis J. Smith. (1990). Effects of Inhaled Leukotriene D ₄ and Platelet-activating Factor on Airway Reactivity in Normal Subjects. American Review of Respiratory Disease. 141(4_pt_1). 993–997. 63 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact